AR065208A1 - Derivados de tetrahidronaftaleno sustituidos con heterociclos o sus analogos bencilsustituidos, metodo de preparacion, medicamentos que los contienen y usos de los mismos, como ligandos de receptores 5-ht7, en patologias asociadas al snc, entre otras. - Google Patents

Derivados de tetrahidronaftaleno sustituidos con heterociclos o sus analogos bencilsustituidos, metodo de preparacion, medicamentos que los contienen y usos de los mismos, como ligandos de receptores 5-ht7, en patologias asociadas al snc, entre otras.

Info

Publication number
AR065208A1
AR065208A1 ARP080100510A ARP080100510A AR065208A1 AR 065208 A1 AR065208 A1 AR 065208A1 AR P080100510 A ARP080100510 A AR P080100510A AR P080100510 A ARP080100510 A AR P080100510A AR 065208 A1 AR065208 A1 AR 065208A1
Authority
AR
Argentina
Prior art keywords
hydrogen
optionally
monosubstituted
unsaturated
saturated
Prior art date
Application number
ARP080100510A
Other languages
English (en)
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38229726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR065208(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of AR065208A1 publication Critical patent/AR065208A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Los procedimientos para su preparacion, medicamentos que comprenden estos compuestos, así como a su uso en la preparacion de un medicamento para el tratamiento de seres humanos o animales, de patologías asociadas al SNC, entre otras. Reivindicacion 1: Derivados de tetrahidro-naftaleno sustituidos con heterociclo de la formula general (1) o su análogo bencil-sustituido de la formula general (2) en la que K-L-M-J forman conjuntamente = CH-X-Y = CH-, en el que cualquier H adecuado puede estar sustituido con R6 y/o R7, y en la cual X se selecciona entre NR8, O o S, mientras que Y se selecciona entre N o CH; = CH-X-Y-C(O)-, en el que cualquier H adecuado puede estar sustituido con R6 y en el cual uno de X e Y es NR8, mientras que el otro se selecciona entre NR8a, S u O; = CH-X-Y-C(O)- en el que uno de X e Y es CH2, mientras que el otro se selecciona entre NR8, S u O, en el que cualquier H adecuado H se puede sustituir por R6 y/o R7; = CR6-N = N-C(O)-; o = CR9- X1 = Y-X2 = CR9a-, en el que dos de Y, X1 y X2 son CH, mientras que el otro se selecciona entre CH o N, en el que cualquier H adecuado puede estar sustituido con R6; R1 se selecciona entre el grupo constituido por hidrogeno; un radical alifático lineal o ramificado, saturado o no saturado, de manera opcional al menos monosustituido; o un alquil-arilo de manera opcional al menos monosustituido; R3 y R4 se seleccionan de manera independiente entre sí entre hidrogeno; halogeno, OH, SH, NH2 un radical alifático lineal o ramificado, saturado o no saturado, de manera opcional al menos monosustituido; u O-R siendo R un radical alifático lineal o ramificado, saturado o no saturado, de manera opcional al menos monosustituido; R6 y R7 se seleccionan de manera independiente entre sí entre hidrogeno; halogeno, OH, SH, NH2 un radical alifático que es lineal o ramificado, saturado o no saturado, de manera opcional al menos monosustituido con F, CI, Br, I, SH u OH; u O-R siendo R un radical alifático que es lineal o ramificado, saturado o no saturado, de manera opcional al menos monosustituido con F, CI, Br, I, SH u OH; R8 y R8a se seleccionan de manera independiente entre sí entre hidrogeno; o un radical alifático que es lineal o ramificado, saturado o no saturado, de manera opcional al menos monosustituido con F, CI, Br, I, SH u OH; R9 y R9a se seleccionan de manera independiente entre sí entre hidrogeno; halogeno, OH, SH, NH2 un radical alifático que es lineal o ramificado, saturado o no saturado, de manera opcional al menos monosustituido con F, CI, Br, I, SH u OH; u O-R siendo R un radical alifático que es lineal o ramificado, saturado o no saturado, de manera opcional al menos monosustituido con F, CI, Br, I, SH u OH; opcionalmente en forma de uno de sus estereoisomeros, preferiblemente enantiomeros o diastereomeros, su racemato o en forma de una mezcla de al menos dos de sus estereoisomeros, preferiblemente enantiomeros o diastereomeros, en cualquier relacion de mezcla, o una sal, preferiblemente una sal fisiologicamente aceptable del mismo, o un solvato correspondiente, respectivamente; con las siguientes condiciones si K-L-M-J forman conjuntamente =CR9-X1=Y-X2=CR9a, en la que X1 y X2 son CH; que si Y es CH, R3 y son hidrogeno, y R9 y R9a son OCH3, entonces R1 no puede ser hidrogeno; que si Y es CH, uno de R3 o R4 es hidrogeno, mientras el otro es OCH3, y uno de R9 y R9a es hidrogeno, mientras el otro es CI, entonces R1 no puede ser metilo; y que si Y es CR6 siendo R6 CF3, uno de R3 o R4 es hidrogeno, mientras el otro es OCH3, y R9 y R9a son hidrogeno, entonces R1 no puede ser metilo; y/o que si Y es CH, uno de R3 o R4 es hidrogeno, mientras el otro es OH, y R9 y R9a son hidrogeno, entonces R1 no puede ser hidrogeno o iso-propilo.
ARP080100510A 2007-02-06 2008-02-06 Derivados de tetrahidronaftaleno sustituidos con heterociclos o sus analogos bencilsustituidos, metodo de preparacion, medicamentos que los contienen y usos de los mismos, como ligandos de receptores 5-ht7, en patologias asociadas al snc, entre otras. AR065208A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07384016A EP1956006A1 (en) 2007-02-06 2007-02-06 Heterocyclyl-substituted-tetrahydro-naphthalen derivatives as 5-HT7 receptor ligands

Publications (1)

Publication Number Publication Date
AR065208A1 true AR065208A1 (es) 2009-05-20

Family

ID=38229726

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100510A AR065208A1 (es) 2007-02-06 2008-02-06 Derivados de tetrahidronaftaleno sustituidos con heterociclos o sus analogos bencilsustituidos, metodo de preparacion, medicamentos que los contienen y usos de los mismos, como ligandos de receptores 5-ht7, en patologias asociadas al snc, entre otras.

Country Status (10)

Country Link
US (1) US8097641B2 (es)
EP (2) EP1956006A1 (es)
JP (1) JP2010517952A (es)
CN (1) CN101636389A (es)
AR (1) AR065208A1 (es)
CA (1) CA2677437A1 (es)
CL (1) CL2008000358A1 (es)
MX (1) MX2009008176A (es)
TW (1) TW200901971A (es)
WO (1) WO2008095689A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1975161A1 (en) * 2007-03-28 2008-10-01 Laboratorios del Dr. Esteve S.A. Heterocyclyl-substituted- tetrahydro-napthalen-amine derivatives, their preparation and use as medicaments
EP2011786A1 (en) * 2007-07-05 2009-01-07 Laboratorios del Dr. Esteve S.A. Indane-amine derivatives, their preparation and use as medicaments
EP2676954A1 (en) 2012-06-19 2013-12-25 Laboratorios del Dr. Esteve S.A. Heterocyclyl-substituted-phenyl derivatives as vasodilators
JP6817073B2 (ja) * 2014-05-19 2021-01-20 ノースイースタン ユニバーシティ セロトニン受容体を標的にする化合物および方法
EP3297979A4 (en) * 2015-05-19 2019-01-09 Northeastern University COMPOUNDS AND METHOD FOR MODULATING SEROTONIN RECEPTORS IN THE PERIPHERAL

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9509156D0 (en) * 1995-05-05 1995-06-28 Sandoz Ltd Organic compounds
DE69829317T2 (de) * 1997-12-25 2006-04-06 Meiji Seika Kaisha Ltd. Tetrahydrobenzindol-derivate
US20040127502A1 (en) * 2001-01-31 2004-07-01 Synaptic Pharmaceutical Corporation Use of GAL3 antagonist for treatment of depression

Also Published As

Publication number Publication date
CN101636389A (zh) 2010-01-27
MX2009008176A (es) 2009-08-12
EP1956006A1 (en) 2008-08-13
WO2008095689A1 (en) 2008-08-14
US8097641B2 (en) 2012-01-17
EP2114893A1 (en) 2009-11-11
CA2677437A1 (en) 2008-08-14
TW200901971A (en) 2009-01-16
JP2010517952A (ja) 2010-05-27
CL2008000358A1 (es) 2008-06-20
US20100035936A1 (en) 2010-02-11

Similar Documents

Publication Publication Date Title
AR067454A1 (es) Derivados de indano- amina, su preparacion y uso como medicamentos
AR035479A1 (es) Derivados de eteres biarilicos y sus sales, composiciones farmaceuticas que los comprenden y procedimientos para el tratamiento de trastornos o afecciones
AR078152A1 (es) Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden
UY28578A1 (es) Derivados de amida
AR065208A1 (es) Derivados de tetrahidronaftaleno sustituidos con heterociclos o sus analogos bencilsustituidos, metodo de preparacion, medicamentos que los contienen y usos de los mismos, como ligandos de receptores 5-ht7, en patologias asociadas al snc, entre otras.
AR041635A1 (es) Compuestos de 4-piperazinilbencenosulfonilindoles, preparacion de los mismos y composiciones farmaceuticas que los contienen
AR078756A1 (es) Moduladores alostericos positivos (map)
AR065464A1 (es) Derivados de nicotinamida. composiciones farmaceuticas
AR050260A1 (es) Derivados de diarilmetilpiperazinas, su preparacion y su utilizacion
ES2169248T3 (es) Compuestos aromaticos y composiciones farmaceuticas que los contienen.
UY28979A1 (es) Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3
AR045155A1 (es) Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos
PE20210465A1 (es) Derivados de tiadiazina
AR045156A1 (es) Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos
AR029373A1 (es) Metodo para el tratamiento de migranas, utilizando compuestos antagonistas selectivos de los receptores iglur5, uso de dichos compuestos antagonistas selectivos en la manufactura de medicamentos para el tratamiento de migranas y dichos compuestos antagonistas
AR062399A1 (es) Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de enfermedades de reaccion a tejido
PE20050293A1 (es) Derivados de aminoacidos sustituidos con cicloalquilo, procedimiento para su preparacion y su uso como medicamentos
AR127050A1 (es) Compuestos espirocíclicos
ES2188743T3 (es) Compuestos de acido pirrolidinilhidroxamico y procedimiento de produccion de los mismos.
AR046874A1 (es) Nuevos metodos
AR064680A1 (es) Derivados de etilamino- fenilo heterociclico sustituidos, su preparacion y su uso como medicamentos
UY28688A1 (es) Derivados de amida
AR008244A1 (es) Compuestos heterociclicos, procedimiento para prepararlos, composiciones farmaceuticas que los comprenden, uso de dichos compuestos en la fabricacion de medicamentos, e intermediarios utiles en la preparacion de dichos compuestos
ES2183492T3 (es) Nuevos derivados de nitrono,su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR042887A1 (es) Derivados de diarilmetiden piperidina preparaciones y usos de los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure